Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Medtronic
McKinsey
Johnson and Johnson
Moodys

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Ipatasertib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Ipatasertib?

Ipatasertib is an investigational drug.

There have been 21 clinical trials for Ipatasertib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 18th 2019.

The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Massachusetts General Hospital.

There are twenty-four US patents protecting this investigational drug and three hundred and eighty-one international patents.

Recent Clinical Trials for Ipatasertib
TitleSponsorPhase
A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.Hoffmann-La RochePhase 3
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast CancerHoffmann-La RochePhase 3
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)Genentech, Inc.Phase 1

See all Ipatasertib clinical trials

Clinical Trial Summary for Ipatasertib

Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib

See all Ipatasertib clinical trials

US Patents for Ipatasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ipatasertib   Start Trial Polymeric nanoparticles and methods of making and using same Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)   Start Trial
Ipatasertib   Start Trial Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use GENENTECH, INC. (South San Francisco, CA)   Start Trial
Ipatasertib   Start Trial Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors Array BioPharma Inc. (Boulder, CO) Covenentech, Inc. (South San Francisco, CA)   Start Trial
Ipatasertib   Start Trial Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors Array Biopharma, Inc. (Boulder, CO) Genentech, Inc. (South San Francisco, CA)   Start Trial
Ipatasertib   Start Trial Combinations of AKT inhibitor compounds and vemurafenib, and methods of use Genentech, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ipatasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Ipatasertib European Patent Office 3119395 2034-03-17   Start Trial
Ipatasertib World Intellectual Property Organization (WIPO) 2015142605 2034-03-17   Start Trial
Ipatasertib Australia 2012236135 2031-04-01   Start Trial
Ipatasertib Australia 2012236138 2031-04-01   Start Trial
Ipatasertib Australia 2012236144 2031-04-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Colorcon
Baxter
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.